You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. CORPORATE - 27-02-2015

    Kedrion unveils its new manufacturing plant in Castelvecchio Pascoli

    The company has invested over 67 million euros and is expected to create between 70 and 90 new jobs

    read more 
  2. CORPORATE - 16-02-2015

    Kedrion CEO took part in "Italy meets the USA" summit on February 10, 2015

    The NY meeting was aimed at highlighting significant investment opportunities in Italy

    read more 
  3. PLASMA & BIOTHERAPIES - 05-02-2015

    SIPPET Study: interim analysis confirms the original hypothesis

    The Study on inhibitors in Hemophilia A is safe to continue after Investigators’ Meeting in San Francisco (Dec 2014)

    read more 

Pages

For more information please contact: pressoffice@kedrion.com